Publisher
Japan Broncho-Esophagological Society
Reference20 articles.
1. 1) Ferris RL, Blumenschein G, Fayette J, et al：Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375：1856-1867, 2016.
2. 2) Brahmer JR, Lacchetti C, Schneider BJ, et al：Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy：American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36：1714-1768, 2018.
3. 3) Haratani K, Hayashi H, Chiba Y, et al：Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer. JAMA Oncol 4：374-378, 2018.
4. 4) Wan H, Mustafa A, Liu S, et al：Immune checkpoint inhibitor toxicity in head and neck cancer：from identification to management. Front Pharmacol 10：1254, 2019.
5. 5) 森 茂彰，加藤久幸，佐藤広生・他：舌根部悪性黒色腫に対するニボルマブの投与後に発現した気管軟骨炎．口咽科32：27-32, 2019.